Essential Medicine
- Stem Cell Therapy
- NAD IV Therapy
- Vitamin IV Therapy
- PRP Therapy
- Ozone Therapy
La Jolla, CA
Psychedelic Therapy clinics in La Jolla
La Jolla has 3 providers offering psychedelic therapy, with ketamine-assisted psychotherapy as the dominant nationwide option. Ketamine is FDA-approved as an anesthetic and Spravato (esketamine) is FDA-approved for treatment-resistant depression, while ketamine-assisted psychotherapy (KAP) is practiced off-label by licensed clinicians. In California, ketamine-assisted psychotherapy is the only medically available psychedelic option. Psilocybin and MDMA remain Schedule I federally. Psilocybin is legal only in Oregon and Colorado under state programs. MDMA-assisted therapy was not approved by the FDA in August 2024 after a Complete Response Letter to Lykos Therapeutics. La Jolla clinics commonly pair ketamine infusions or IM injections with therapy sessions, typical packages run 2,500 to 6,000 dollars for a six-session protocol, and Spravato is covered by many insurers when criteria are met. Psilocybin and MDMA remain federally illegal, and the FDA issued a Complete Response Letter to Lykos Therapeutics in August 2024 for MDMA-assisted therapy for PTSD. A reputable La Jolla provider will screen for cardiovascular risk, psychiatric history, and concurrent medications before starting treatment.
Kadima Neuropsychiatry Institute
- Transcranial Magnetic Stimulation (TMS)
- Ketamine Therapy
- Psychedelic Therapy
MD on staff
Kadima Neuropsychiatry Institute
- Ozone Therapy
- IV Therapy
- Transcranial Magnetic Stimulation (TMS)
- Hyperbaric Oxygen Therapy (HBOT)
- Ketamine Therapy
MD on staff
Essential Medicine
- Ozone Therapy
- IV Therapy
- Hyperbaric Oxygen Therapy (HBOT)
- Ketamine Therapy
- Arthritis Treatment
Regulatory context
A note on California's psychedelic therapy rules.
Ketamine is a DEA Schedule III controlled substance, FDA-approved as a dissociative anesthetic and used off-label for treatment-resistant depression, PTSD, and chronic pain. The FDA approved esketamine (Spravato) in 2019 for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) program that requires in-office administration at certified sites. MDMA-assisted therapy remains Schedule I; the FDA issued a Complete Response Letter in August 2024 to Lykos Therapeutics on its MDMA new drug application. Psilocybin is Schedule I and holds FDA Breakthrough Therapy designation through sponsors such as Compass Pathways and Usona, but has not received FDA approval. Oregon Measure 109 (passed 2020, operational 2023) created a state psilocybin service center framework, and Colorado Proposition 122 (2022) authorized regulated healing centers.
-
SB 803 (2023, vetoed) and SB 1012 (2024, stalled)
Proposed regulated therapeutic access to psilocybin, MDMA, mescaline, and DMT; Governor Newsom vetoed SB 58 (2023) citing lack of treatment guidelines. -
Local decriminalization resolutions
Oakland (2019), Santa Cruz (2020), Arcata, San Francisco, and Berkeley have passed non-binding resolutions deprioritizing enforcement of natural psychedelics; no legal therapeutic framework.
California enforces federal DEA scheduling. The Medical Board of California investigates prescriber misconduct, including ketamine diversion and inadequate patient monitoring. Several high-profile California ketamine-related deaths (including Matthew Perry's 2023 overdose) have intensified board scrutiny of clinic practices. DEA enforcement targets compounding, diversion, and Ryan Haight Act telehealth compliance.